One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model

• DOI: 10.1016/j.vaccine.2021.06.057
• Publication Date: 2021-06-23T15:53:25Z
• Authors: Karen E. Gooch; Trevor R.F. Smith; Francisco J. Salg...; Susan A. Fotherin...; Robert J. Watson; Mike J. Dennis; Alastair Handley; Holly E. Humphries; Stephanie Longet; Tom Tipton; Charlotte Sarfas; Laura Sibley; Gillian S. Slack; Emma Rayner; Kathryn A. Ryan; Katherine Schultheis; Stephanie J. Ramos; Andrew White; Sue Charlton; Sally A. Sharpe; Fergus Gleeson; Laurent M. Humeau; Yper Hall; Kate E. Broderick; Miles W. Carroll
• Keywords: Rhesus macaque; Regimen

Safe and effective vaccines will provide essential medical countermeasures to tackle the COVID-19 pandemic. Here, we assessed safety, immunogenicity efficacy of intradermal delivery INO-4800, a synthetic DNA vaccine candidate encoding SARS-CoV-2 spike protein in rhesus macaque model. Single 2 dose vaccination regimens were evaluated. Vaccination induced both binding neutralizing antibodies, along with IFN-γ-producing T cells against SARS-CoV-2. Upon administration high viral (5 × 10